plasugrel is a novel thienopyridine antiplatelet agent
(different in structure but same mechanism of action)
prasugrel provides greater and more consistent platelet
inhibition than clopidogrel due to earlier and more extensive
formation of active metabolite.
plasugrel absorbs rapidly and extensively where
clopidogrelabsorption is limited.
plasugrel is rapidly hydrolyzed and metabolism is extensive as
parent drug cannot be detected in plasma while the majority of
clopidogrel is metabolized into inactive metabolites by
deesterification.
plasugrel has greater and more rapid platelet inhibition than
clopidogrel.